Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00262080 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT00262080 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 91 participants.
The verdict
NCT00262080, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe acute attacks of HAE.
Interventions
- DRUG ecallantide
- DRUG Phosphate Buffer Saline (PBS),
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2005-12-31 |
| Est. Completion | 2007-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00262080
The ClinicalTrials.gov registry entry for NCT00262080 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ecallantide is the first listed.
NCT00262080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00262080 about?
NCT00262080 is a clinical study titled "Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)". The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe acute attacks of HAE.
What is the current status of trial NCT00262080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2005-12-31. Estimated completion is 2007-02-28.
What interventions are being tested in trial NCT00262080?
The interventions under investigation include: ecallantide (DRUG), Phosphate Buffer Saline (PBS), (DRUG).
Who is sponsoring clinical trial NCT00262080?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.